MASLD has become the most common chronic liver disease worldwide. The authors review the features of the disease as well as ...

More than one in five UK adults tried to access weight-loss medications in the past year alone, according to a survey by the ...

Among the many forms of liver cancer, hepatocellular carcinoma (HCC) is the most common and one of the leading causes of ...

Tirzepatide (GIP + GLP-1) has also been shown to reduce cardiovascular risk. In an international trial of 713 adults in nine ...

Obesity medicine specialist Sue Pedersen says the updates also focus on individualizing care and move away from relying on ...

Researchers at the Salk Institute have used CRISPR to uncover hidden microproteins that control fat cell growth and lipid ...

When Hannah Fewtrell found herself, at the age of 49, constantly exhausted with low mood - shadows etched beneath her eyes, ...

However, the late-stage study results fell short of Novo Nordisk ’s injectable Wegovy, which delivered 14.9 per cent weight loss over 68 weeks in a 2021 trial. Lilly shares plummeted 14 per cent in ...

Eli Lilly said on Thursday that its experimental GLP-1 pill helped patients lose 12.4% of their body weight in a late-stage study, but that was less than previous trial results for Novo Nordisk's ...

As announced July 29, Novo Nordisk NVO saw 18% sales growth and 40% operating profit growth at constant currencies in the second quarter. However, management reduced 2025 growth guidance for sales (8% ...

Novo Nordisk A/S (NYSE:NVO) on Wednesday reported second-quarter 2025 sales of roughly $11.68 billion (76.86 billion Danish ...